



**Newly Reported Substances:** The following substances were reported to NFLIS-Drug for the first time between **January 1, 2023, and March 31, 2023.**




**South**



**Hydroxetamine**




**N-Methylclonazepam**



**Midwest**

**Methoxisopropamine**



**Snapshot of Drug Reports Received by NFLIS-Drug**


The tables on the right present the top five drug reports in each category received by NFLIS-Drug between January 1, 2023, and March 31, 2023.

Synthetic Cathinones	2,954	Steroids	378	Selected Benzimidazole Opioids	282
Dipentylone	1,972	Testosterone	174	Metonitazene	147
alpha-PiHP	267	Trenbolone	41	Protonitazene	91
N-Cyclohexylmethylone	257	Nandrolone	33	Etodesnitazene	19
Eutylone	244	Methandrostebolone	28	Isotonitazene	17
alpha-PHP	47	Oxandrolone	26	Flunitazene	8


**Medetomidine and Xylazine Combinations**

The following figures show substances that were reported to NFLIS-Drug in combination with medetomidine or xylazine between January 1, 2022, and December 31, 2022. The data presented in this section are not necessarily counts of true combinations (e.g., powders mixed together), but also include counts of separate drugs reported together in the same item.


Percentage of Items Containing Medetomidine and at Least One Other Drug




Percentage of All Medetomidine Items That Include Other Drugs



Percentage of Items Containing Xylazine and at Least One Other Drug



Percentage of All Xylazine Items That Include Other Drugs



<sup>1</sup> Includes all positional and nonspecified isomers as reported by participating laboratories.

**Data Disclaimer:** Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in April 2023. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after January 1, 2022. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.dea/diversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.dea/diversion.usdoj.gov/publicationsRedesign.xhtml>. Questions and comments: [NFLIS@dea.gov](mailto:NFLIS@dea.gov)

